Second, while our identified consensus groups across different GEP signatures were associated with key clinicopathological and molecular variables in adenocarcinoma, such as smoking status, tumor stage, gender, and mutational patterns of EGFR and KRAS, we observed heterogeneity for all these traits across consensus groups (Figure 5). This evidence concerns the gene KRAS and adenocarcinoma.